News | Cancer

Feature

How can pharmacists best support patients with chronic lymphocytic leukaemia?

As therapies for chronic lymphocytic leukaemia have evolved, so has pharmacists’ role in treating people with this type of blood cancer.…

Published: 20 September 2024

Supported content

Opinion

PJ view: Current testing for genetic variants risks undoing years of progress on health inequalities

It is crucial that the NHS prioritises health equity as pharmacogenomic testing gains traction in day-to-day UK healthcare.…

Published: 8 August 2024

News

Screening for gene variants should be broadened to reduce health inequalities, systematic review concludes

Study authors have called for an extension to DPYD genetic testing in the UK, to include variants identified in people with African ancestry.…

Published: 31 July 2024

News

MHRA approves capivasertib for treatment of advanced breast cancer

Capivasertib is an oral pill given with fulvestrant, a hormonal therapy, as an alternative treatment to endocrine-based regimens.…

Published: 25 July 2024

News

Draft NICE guidance recommends ‘at-home’ pill for advance prostate cancer

The National institute of Health and Care Excellence says up to 40,000 people in England could benefit from relugolix (Orgovyx; Accord).…

Published: 22 July 2024

Feature

Medical drone deliveries: a viable option for the NHS?

In this episode of The PJ Pod, we speak to experts who are testing the feasibility of using drones to deliver NHS medicines.…

Published: 10 July 2024

Feature

How AI is transforming drug discovery

Pharmaceutical companies and start-ups are harnessing AI to improve speed and reduce costs at every stage of the drug discovery and development process.…

Published: 3 July 2024

News

Combination treatment before surgery improves melanoma survival rates, study results show

The 12-month event-free survival rate for patients with macroscopic stage III node-positive melanoma was 83.7% with the combination treatment, compared with 57.2% for adjuvant therapy alone.…

Published: 11 June 2024

News

Osimertinib treatment for advanced non-small cell lung cancer increases survival rates, study finds

Patients treated with osimertinib had an average of 39.1 months of progression-free survival, compared with 5.6 months in those given placebo.…

Published: 5 June 2024

Opinion

Why we are helping patients with lung cancer symptoms self-refer for a chest X-ray

Pharmacies in Leeds are helping to diagnose lung cancer earlier by piloting a service that allows patients with red-flag symptoms to refer themselves to hospital for testing.…

Published: 8 May 2024